Darby Erler1, Drew Brotherston2, Arjun Sahgal1, Patrick Cheung1, Andrew Loblaw3, William Chu1, Hany Soliman1, Hans Chung1, Alex Kiss4, Edward Chow1, Ian Poon5. 1. Sunnybrook Odette Cancer Centre, Department of Radiation Oncology, University of Toronto, Canada. 2. Faculty of Medicine, University of Toronto, Canada. 3. Sunnybrook Odette Cancer Centre, Department of Radiation Oncology, University of Toronto, Canada; Institute of Health Policy, Management & Evaluation, University of Toronto, Canada. 4. Institute of Health Policy, Management & Evaluation, University of Toronto, Canada; Department of Research Design and Biostatistics, Sunnybrook Research Institute, Canada. 5. Sunnybrook Odette Cancer Centre, Department of Radiation Oncology, University of Toronto, Canada. Electronic address: ian.poon@sunnybrook.ca.
Abstract
AIMS: To report local control and toxicity rates for patients treated with stereotactic body radiotherapy (SBRT) for non-spine bone metastases. METHODS AND MATERIALS: Eighty-one patients with 106 non-spine bone metastases were treated between 2011 and 2014 and retrospectively reviewed. Indications included: oligometastases (63%), oligoprogression (17.3%), retreatment (2.4%) or other (17.3%). Cumulative incidence function was used to assess local recurrence and fracture probability. Bivariate relationships were investigated based on selected patient, tumour and dose-volume factors. RESULTS: Mean follow-up was 13 months (range, 0.25-45.6) and the median patient age was 66.4 years (range, 36-86). Most patients were male (60.5%) and the predominant histology prostate cancer (32%). Bone metastases were most commonly located in the pelvis (41.5%) and almost half sclerotic. The most common prescriptions were 30 Gy/5 (30.2%) and 35 Gy/5 (42.5%). The cumulative incidence of local recurrence at 6,18 and 24 months respectively was 4.7%, 8.3% and 13.3% with a mean time to local recurrence of 11.8 months (range, 3.9-23.4). A significant association was found between local recurrence and volume of the PTV (p = 0.02), with larger PTVs having a greater risk of local failure. Fracture was observed radiographically in the treatment volume in 9/106 (8.5%) of treated lesions and the mean time to fracture was 8.4 months (range, 0.7-32.5 months). With respect to predictors, a trend was observed for lytic lesions (p = 0.11) and female gender (p = 0.09). CONCLUSIONS: The results of this study confirm that SBRT yields high rates of long-term local control for non-spine bone metastases with a low fracture risk.
AIMS: To report local control and toxicity rates for patients treated with stereotactic body radiotherapy (SBRT) for non-spine bone metastases. METHODS AND MATERIALS: Eighty-one patients with 106 non-spine bone metastases were treated between 2011 and 2014 and retrospectively reviewed. Indications included: oligometastases (63%), oligoprogression (17.3%), retreatment (2.4%) or other (17.3%). Cumulative incidence function was used to assess local recurrence and fracture probability. Bivariate relationships were investigated based on selected patient, tumour and dose-volume factors. RESULTS: Mean follow-up was 13 months (range, 0.25-45.6) and the median patient age was 66.4 years (range, 36-86). Most patients were male (60.5%) and the predominant histology prostate cancer (32%). Bone metastases were most commonly located in the pelvis (41.5%) and almost half sclerotic. The most common prescriptions were 30 Gy/5 (30.2%) and 35 Gy/5 (42.5%). The cumulative incidence of local recurrence at 6,18 and 24 months respectively was 4.7%, 8.3% and 13.3% with a mean time to local recurrence of 11.8 months (range, 3.9-23.4). A significant association was found between local recurrence and volume of the PTV (p = 0.02), with larger PTVs having a greater risk of local failure. Fracture was observed radiographically in the treatment volume in 9/106 (8.5%) of treated lesions and the mean time to fracture was 8.4 months (range, 0.7-32.5 months). With respect to predictors, a trend was observed for lytic lesions (p = 0.11) and female gender (p = 0.09). CONCLUSIONS: The results of this study confirm that SBRT yields high rates of long-term local control for non-spine bone metastases with a low fracture risk.
Authors: Roman O Kowalchuk; Michael R Waters; K Martin Richardson; Kelly Spencer; James M Larner; Jason P Sheehan; William H McAllister; Charles R Kersh Journal: J Radiosurg SBRT Date: 2020
Authors: Quynh-Nhu Nguyen; Stephen G Chun; Edward Chow; Ritsuko Komaki; Zhongxing Liao; Rensi Zacharia; Bill K Szeto; James W Welsh; Stephen M Hahn; C David Fuller; Bryan S Moon; Justin E Bird; Robert Satcher; Patrick P Lin; Melenda Jeter; Michael S O'Reilly; Valerae O Lewis Journal: JAMA Oncol Date: 2019-06-01 Impact factor: 31.777
Authors: Yilin Cao; Gregory C Stachelek; Wei Fu; Daniel Y Song; Russell K Hales; K Ranh Voong; Jeffrey J Meyer; Harry Quon; Chen Hu; Kristin J Redmond Journal: J Radiosurg SBRT Date: 2021
Authors: Samuel Finkelstein; Srinivas Raman; Joanne Van Der Velden; Liying Zhang; Carolyn Tan; Amanpreet Dhillon; Frances Tonolete; Nicholas Chiu; Linda Probyn; Rachel McDonald; Arjun Sahgal; Edward Chow; Lee Chin Journal: Technol Cancer Res Treat Date: 2019-01-01